Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SYNCOM FORMULATIONS vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SYNCOM FORMULATIONS   ACTAVIS
EQUITY SHARE DATA
    SYNCOM FORMULATIONS
Mar-23
ACTAVIS
Dec-18
SYNCOM FORMULATIONS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1316,126-   
Low Rs510,818-   
Sales per share (Unadj.) Rs2.43,955.8-  
Earnings per share (Unadj.) Rs0.2-1,274.2-  
Cash flow per share (Unadj.) Rs0.3416.9-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs2.716,315.7-  
Shares outstanding (eoy) m940.00332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.73.4 108.0%   
Avg P/E ratio x41.1-10.6 -388.7%  
P/CF ratio (eoy) x33.532.3 103.7%  
Price / Book Value ratio x3.20.8 390.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,2494,480,758 0.2%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m2440-   
Avg. sales/employee Rs Th077,851.4-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,076.0-  
INCOME DATA
Net Sales Rs m2,2431,315,689 0.2%  
Other income Rs m14625,160 0.6%   
Total revenues Rs m2,3891,340,849 0.2%   
Gross profit Rs m19934,478 0.6%  
Depreciation Rs m45562,428 0.0%   
Interest Rs m3475,923 0.0%   
Profit before tax Rs m266-578,713 -0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,595 0.0%   
Tax Rs m65-7,334 -0.9%   
Profit after tax Rs m201-423,784 -0.0%  
Gross profit margin %8.92.6 338.9%  
Effective tax rate %24.51.3 1,930.8%   
Net profit margin %8.9-32.2 -27.8%  
BALANCE SHEET DATA
Current assets Rs m1,817539,627 0.3%   
Current liabilities Rs m1,132477,372 0.2%   
Net working cap to sales %30.64.7 645.8%  
Current ratio x1.61.1 142.0%  
Inventory Days Days23120 1,181.0%  
Debtors Days Days1,22966 1,853.4%  
Net fixed assets Rs m1,961148,929 1.3%   
Share capital Rs m9400-   
"Free" reserves Rs m1,6200-   
Net worth Rs m2,5605,426,601 0.0%   
Long term debt Rs m01,910,903 0.0%   
Total assets Rs m3,7788,483,012 0.0%  
Interest coverage x8.8-6.6 -133.1%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.2 382.7%   
Return on assets %6.2-4.1 -151.5%  
Return on equity %7.8-7.8 -100.4%  
Return on capital %11.7-4.8 -241.9%  
Exports to sales %63.30-   
Imports to sales %7.70-   
Net fx Rs m1,2150-   
CASH FLOW
From Operations Rs m105470,046 0.0%  
From Investments Rs m-450258,229 -0.2%  
From Financial Activity Rs m350-806,740 -0.0%  
Net Cashflow Rs m6-78,073 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare SYNCOM FORMULATIONS With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare SYNCOM FORMULATIONS With: PARNAX LAB  KABRA DRUGS  FERMENTA BIOTECH  MEDICAMEN BI  SHAMROCK IND  



Today's Market

Sensex Today Tanks 609 Points | Auto Stocks Drag | Bajaj Finance, L&T Technology Sink 7% Sensex Today Tanks 609 Points | Auto Stocks Drag | Bajaj Finance, L&T Technology Sink 7%(Closing)

After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.